News

A £10 billion ‘megafund’ to help UK pharma firms develop new drugs will be discussed at a conference held by the mayor of London’s office today.

AbbVie has unveiled late-stage clinical trial data showing a sustained response to its all oral, interferon-free Viekirax-based hepatitis C regimen.

Basilea Pharmaceutica has launched its new broad-spectrum antibiotic Cephalosporin Zevtera across the UK for the first-line treatment of serious bacterial pneumonia, offering patients a new weapon in the fight against the infection.

Bristol-Myers Squibb is pulling the plug on its discovery research in virology as part of an R&D reshuffle plans for which first surfaced back in 2013, leading to cull of around 100 related positions.

Community pharmacists are to get access to Summary Care Records under new plans unveiled this week by the Health and Social Care Information Centre.

Daiichi Sankyo’s once-daily bloodthinner Lixiana has been approved for use across the European Union for stroke prophylaxis and to prevent and treat certain blood clots.

Novo Nordisk has presented interim data showing that its coagulant NovoEight is safe and effective in preventing and treating bleeds in people with severe haemophilia A in the long term.

PAREXEL International is shedding up to 850 positions as part of a restructuring programme designed to ramp up productivity and efficiency. 

A new YouGov poll suggests that the UK public views care for the elderly and weekend access to GPs as the top priorities for the NHS.

Roche is expanding its footprint in Africa with a new strategy designed to tap into the “growing economic might of the continent and potential to do business in”.

Organiser PharmaTimes Media is delighted to announce details of the first of the free workshops that will be running...

Join us for a glittering gala dinner at the Park Plaza Riverbank as we celebrate the achievements of sales...

The National Institute for Heath and Care Excellence is calling on employers to recognise the value of a healthy workplace, as figures show an estimated 27 million working days are lost because of work-related illness at a cost to society of some £13 billion a year.

Cost regulators for the NHS in England and Wales are asking for more information on Santen’s dry eye treatment Ikervis because the evidence provided is too uncertain.

Valeant and Progenics have filed an application in the US to market an oral form of Relistor for opioid-induced constipation in adult patients with chronic non-cancer pain.